<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Merck (MRK) And Daiichi Sankyo&#x27;s R-DXd Receives FDA Breakthrough Therapy Designation — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Merck (MRK) And Daiichi Sankyo&#x27;s R-DXd Receives FDA Breakthrough Therapy Designation</h2>
    <div class="badge">2025-09-15T17:27:14+00:00</div>
    <ul>
      <li>Current share prices reflect a discount of approximately 23.6% compared to the consensus analyst price target of US$102.33.</li>
<li>Over the past five years, Merck&#x27;s total shareholder return, incorporating both share price appreciation and dividends, was 21.17%.</li>
<li>Notably, its yearly performance has also been weaker compared to peers in the US Pharmaceuticals industry, which saw a 12.5% decline.</li>
<li>This figure illustrates a steady growth trajectory, yet the company has underperformed the US market&#x27;s 18.5% return over the past year.</li>
<li>Merck experienced a 6% rise in its share price over the last quarter, coinciding with significant developments such as the FDA granting Breakthrough Therapy Designation for raludotatug deruxtecan—a potential first-in-cla</li>
<li>Find out which 28 stocks are leading the charge.</li>
<li>We&#x27;ve discovered 1 weakness for Merck that you should be aware of before investing here.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Merck (MRK) And Daiichi Sankyo&amp;#x27;s R-DXd Receives FDA Breakthrough Therapy Designation\n• Current share prices reflect a discount of approximately 23.6% compared to the consensus analyst price target of US$102.33.\n• Over the past five years, Merck&#x27;s total shareholder return, incorporating both share price appreciation and dividends, was 21.17%.\n• Notably, its yearly performance has also been weaker compared to peers in the US Pharmaceuticals industry, which saw a 12.5% decline.\n• This figure illustrates a steady growth trajectory, yet the company has underperformed the US market&#x27;s 18.5% return over the past year.\n• Merck experienced a 6% rise in its share price over the last quarter, coinciding with significant developments such as the FDA granting Breakthrough Therapy Designation for raludotatug deruxtecan—a potential first-in-cla\n• Find out which 28 stocks are leading the charge.\n• We&#x27;ve discovered 1 weakness for Merck that you should be aware of before investing here." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/merck-mrk-daiichi-sankyos-r-172714735.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>